WePeptideRx review

WePeptideRx presents compounded injections, oral semaglutide tablets and approved brand-name injections with consultation and shipping in the advertised package. Its product pages provide dose selectors and distinguish shorter supplies from longer programs. However, current selectors and explanatory text disagree on prices. The semaglutide selector labels one set of figures as regular pricing after the first order, while the overview and supply cards give higher figures. Oral and longer-program figures differ too. Similar discrepancies appear on brand product pages. Obtain a written quote identifying the selected formulation, supply, initial charge and subsequent charge before relying on any advertised starting price. The tirzepatide cost guide explains why an unresolved price should not become an annual budget.

A selector can help reveal that dose choices carry different prices, but it cannot establish what your future clinician-directed prescription will cost. Your provider determines the appropriate preparation and treatment, rather than a shopping dropdown deciding your dose. The monthly compounded descriptions include B12 and may include glycine; the longer-program description says glycine is not included there. An oral dissolving tablet is also a different preparation from an approved oral brand. A lower advertised amount or a vitamin blend does not prove equivalent absorption, better tolerability or additional clinical benefit. The compounded tirzepatide guide describes the evidence and regulatory distinctions to discuss with the clinician.

The current refund policy makes the payment sequence clear: checkout occurs before clinical review and reserves the consultation. The consultation is included, rather than a second visit fee. If the provider declines the requested treatment, the company says that item is refunded to the original card, normally within five business days after the decision, with additional bank posting time possible. This is not a guarantee of immediate access to the money or approval for another therapy. Medication that has been dispensed and shipped is nonrefundable. The policy asks for damaged, incorrect or quality-problem reports within 48 hours of delivery and describes pharmacy coordination that may include replacement. A lost shipment has a separate carrier-search and replacement process.

Subscription cancellation or a pause must be requested through support before the next billing cycle to avoid the upcoming charge. The reviewed policy does not give a fixed advance-notice interval or establish a self-service cancellation button. Ask for the next processing date and retain written confirmation; stopping injections does not itself cancel a subscription. Brand pages describe four-pen, 28-day supplies, while some supply cards call the purchase one-time. Supply duration alone does not establish automatic 28-day billing. Confirm whether you are authorizing a single purchase or recurring charge, instead of assuming a fixed number of annual payments. Shipping is advertised as three to five business days for approved orders, following clinical review; it is not guaranteed delivery within a day of checkout.

PureRx Biotech INC, doing business as WePeptideRx, is the platform operator named in the terms. Its telehealth disclosure describes an independent third-party provider network and names Hridyesh Nat as medical director. Those credential and licensure statements are company disclosures, not independent confirmation of your assigned practitioner. The company says treating-provider identity and state licensure are available before and during consultation; request them and the dispensing pharmacy before treatment. The current state page lists 48 states, excluding Alabama and Mississippi, but explicitly warns that some therapies are unavailable even in active states. A listed state is therefore not proof that every compounded or brand product can be supplied there. The pharmacy-checking guide and pill comparison help organize those questions. Microdose advertising does not establish a benefit, a safer treatment or suitability for a person who does not meet an approved product’s indication.